RDY
HealthcareDr. Reddy's Laboratories Limited
$13.82
$-0.04 (-0.29%)
Jan 5, 2026
Price History (1Y)
Analysis
Dr. Reddy's Laboratories Limited is a leading company in the healthcare sector, specifically operating within the drug manufacturers - specialty & generic industry. The company has a significant market presence with a market capitalization of $11.51 billion and revenue of $342.15 billion (TTM). Additionally, Dr. Reddy's employs approximately 27,811 people globally. The financial health of Dr. Reddy's is characterized by moderate profitability, with gross margin, operating margin, and profit margin standing at 56.4%, 18.4%, and 17.1% respectively. The company's returns on equity (ROE) and return on assets (ROA) are 17.4% and 8.8% respectively. Dr. Reddy's balance sheet reveals a debt-to-equity ratio of 16.17, indicating a relatively high level of leverage, while its cash position stands at $69.81 billion. The valuation of Dr. Reddy's can be contextualized by its price-to-earnings (P/E) ratio of 17.72 (TTM), forward P/E of 21.97, and price-to-book of 2.89. The company has demonstrated revenue growth of 9.8% (YoY) and earnings growth of 14.6% (YoY). Dr. Reddy's also pays a dividend with a yield of 66.0%, supporting a payout ratio of 11.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Visit website →Key Statistics
- Market Cap
- $11.51B
- P/E Ratio
- 17.72
- 52-Week High
- $16.17
- 52-Week Low
- $12.26
- Avg Volume
- 1.10M
- Beta
- 0.32
- Dividend Yield
- 66.00%
Company Info
- Exchange
- NYQ
- Country
- India
- Employees
- 27,811